CN1425448A - 一种治疗血栓性静脉炎的药物 - Google Patents
一种治疗血栓性静脉炎的药物 Download PDFInfo
- Publication number
- CN1425448A CN1425448A CN03100187A CN03100187A CN1425448A CN 1425448 A CN1425448 A CN 1425448A CN 03100187 A CN03100187 A CN 03100187A CN 03100187 A CN03100187 A CN 03100187A CN 1425448 A CN1425448 A CN 1425448A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- scorpio
- ethanol
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 229940079593 drug Drugs 0.000 title claims description 8
- 230000001732 thrombotic effect Effects 0.000 title abstract description 4
- 208000001297 phlebitis Diseases 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 80
- 239000008187 granular material Substances 0.000 claims description 57
- 241000131808 Scolopendra Species 0.000 claims description 30
- 241000522620 Scorpio Species 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 30
- 239000009490 scorpio Substances 0.000 claims description 30
- 238000004821 distillation Methods 0.000 claims description 28
- 239000009636 Huang Qi Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 23
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 23
- 210000000582 semen Anatomy 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 241000237903 Hirudo Species 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 241000628997 Flos Species 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 241001570521 Lonicera periclymenum Species 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- 238000001256 steam distillation Methods 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 9
- 239000000080 wetting agent Substances 0.000 claims description 9
- 239000007779 soft material Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 201000005060 thrombophlebitis Diseases 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 241000202807 Glycyrrhiza Species 0.000 claims description 2
- 241000245240 Lonicera Species 0.000 claims description 2
- 241001530126 Scrophularia Species 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 4
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 48
- 229960004756 ethanol Drugs 0.000 description 31
- 239000011734 sodium Substances 0.000 description 30
- 239000008899 fufang danshen Substances 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 24
- 210000002381 plasma Anatomy 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 210000001367 artery Anatomy 0.000 description 15
- 230000008961 swelling Effects 0.000 description 15
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
- 210000003462 vein Anatomy 0.000 description 14
- 208000007536 Thrombosis Diseases 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 10
- 210000003414 extremity Anatomy 0.000 description 10
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 231100000915 pathological change Toxicity 0.000 description 8
- 230000036285 pathological change Effects 0.000 description 8
- 206010047249 Venous thrombosis Diseases 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 235000009161 Espostoa lanata Nutrition 0.000 description 6
- 240000001624 Espostoa lanata Species 0.000 description 6
- 108010049003 Fibrinogen Proteins 0.000 description 6
- 102000008946 Fibrinogen Human genes 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 6
- 102100027378 Prothrombin Human genes 0.000 description 6
- 229940012952 fibrinogen Drugs 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 229940039716 prothrombin Drugs 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 5
- 239000005639 Lauric acid Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 210000000078 claw Anatomy 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 4
- 206010051055 Deep vein thrombosis Diseases 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000001105 femoral artery Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 206010017711 Gangrene Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- -1 lipid peroxide Chemical class 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 208000033386 Buerger disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004231 tunica media Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101000651443 Rattus norvegicus Prothrombin Proteins 0.000 description 1
- 206010043595 Thrombophlebitis superficial Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031001874A CN1201787C (zh) | 2002-08-07 | 2003-01-09 | 一种治疗血栓性静脉炎的药物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN02125974 | 2002-08-07 | ||
CN02125974.7 | 2002-08-07 | ||
CNB031001874A CN1201787C (zh) | 2002-08-07 | 2003-01-09 | 一种治疗血栓性静脉炎的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1425448A true CN1425448A (zh) | 2003-06-25 |
CN1201787C CN1201787C (zh) | 2005-05-18 |
Family
ID=25741156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031001874A Expired - Lifetime CN1201787C (zh) | 2002-08-07 | 2003-01-09 | 一种治疗血栓性静脉炎的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1201787C (zh) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101618161B (zh) * | 2008-07-05 | 2011-01-26 | 鲁南厚普制药有限公司 | 一种治疗血栓性静脉炎的中药组合物及其制备方法 |
CN101961465A (zh) * | 2010-09-28 | 2011-02-02 | 牛秀峰 | 治疗门静脉系统血栓的中药 |
CN102671054A (zh) * | 2012-06-12 | 2012-09-19 | 赵国藏 | 治疗血栓性静脉炎的中药组合物 |
CN103933410A (zh) * | 2013-01-21 | 2014-07-23 | 鲁南制药集团股份有限公司 | 一种中药组合物的医药用途及其制备方法 |
CN104721741A (zh) * | 2015-03-19 | 2015-06-24 | 济南鸿飞生物技术有限公司 | 一种治疗虚寒型血栓性静脉炎的药物及其制备方法 |
CN104784579A (zh) * | 2015-05-14 | 2015-07-22 | 南京华宽信息咨询中心 | 一种治疗血栓闭塞性脉管炎的中药组合物 |
CN105288392A (zh) * | 2015-11-30 | 2016-02-03 | 吕翠云 | 一种治疗血栓闭塞性脉管炎的中药 |
CN105456585A (zh) * | 2015-12-24 | 2016-04-06 | 郭效东 | 一种治疗静脉炎的中药制剂及制备方法 |
CN106822849A (zh) * | 2017-03-30 | 2017-06-13 | 蒋世芬 | 血栓性静脉炎的治疗药物 |
CN109260397A (zh) * | 2017-07-18 | 2019-01-25 | 鲁南制药集团股份有限公司 | 一种治疗眼底血管性疾病的中药组合物 |
CN109718341A (zh) * | 2017-10-31 | 2019-05-07 | 鲁南制药集团股份有限公司 | 一种治疗无菌性股骨头坏死的中药组合物 |
CN110123968A (zh) * | 2019-06-20 | 2019-08-16 | 鲁南制药集团股份有限公司 | 一种脉络舒通制剂的制备方法 |
CN110732003A (zh) * | 2018-07-18 | 2020-01-31 | 鲁南制药集团股份有限公司 | 一种治疗脑卒中后遗症的中药组合物 |
CN110732004A (zh) * | 2018-07-18 | 2020-01-31 | 鲁南制药集团股份有限公司 | 一种治疗脑供血不足的中药组合物 |
CN111228419A (zh) * | 2018-11-28 | 2020-06-05 | 鲁南制药集团股份有限公司 | 一种脉络舒通微丸制剂及其制备方法 |
WO2021042276A1 (zh) * | 2019-09-03 | 2021-03-11 | 鲁南制药集团股份有限公司 | 一种治疗骨性关节炎的联合用药物 |
WO2021042274A1 (zh) * | 2019-09-03 | 2021-03-11 | 鲁南制药集团股份有限公司 | 一种治疗骨性关节炎的中西药组合物 |
WO2021042275A1 (zh) * | 2019-09-03 | 2021-03-11 | 鲁南制药集团股份有限公司 | 一种治疗骨性关节炎的的中药组合物 |
CN114470114A (zh) * | 2022-01-27 | 2022-05-13 | 山东新时代药业有限公司 | 脉络舒通制剂在制备治疗便秘药物中的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114159530A (zh) * | 2020-09-11 | 2022-03-11 | 鲁南制药集团股份有限公司 | 脉络舒通制剂在制备治疗雷诺综合症药物中的用途 |
-
2003
- 2003-01-09 CN CNB031001874A patent/CN1201787C/zh not_active Expired - Lifetime
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101618161B (zh) * | 2008-07-05 | 2011-01-26 | 鲁南厚普制药有限公司 | 一种治疗血栓性静脉炎的中药组合物及其制备方法 |
CN101961465A (zh) * | 2010-09-28 | 2011-02-02 | 牛秀峰 | 治疗门静脉系统血栓的中药 |
CN101961465B (zh) * | 2010-09-28 | 2012-07-18 | 牛秀峰 | 治疗门静脉系统血栓的中药 |
CN102671054A (zh) * | 2012-06-12 | 2012-09-19 | 赵国藏 | 治疗血栓性静脉炎的中药组合物 |
CN102671054B (zh) * | 2012-06-12 | 2014-06-18 | 赵国藏 | 治疗血栓性静脉炎的中药组合物 |
CN103933410A (zh) * | 2013-01-21 | 2014-07-23 | 鲁南制药集团股份有限公司 | 一种中药组合物的医药用途及其制备方法 |
CN104721741A (zh) * | 2015-03-19 | 2015-06-24 | 济南鸿飞生物技术有限公司 | 一种治疗虚寒型血栓性静脉炎的药物及其制备方法 |
CN104784579A (zh) * | 2015-05-14 | 2015-07-22 | 南京华宽信息咨询中心 | 一种治疗血栓闭塞性脉管炎的中药组合物 |
CN105288392A (zh) * | 2015-11-30 | 2016-02-03 | 吕翠云 | 一种治疗血栓闭塞性脉管炎的中药 |
CN105456585A (zh) * | 2015-12-24 | 2016-04-06 | 郭效东 | 一种治疗静脉炎的中药制剂及制备方法 |
CN106822849A (zh) * | 2017-03-30 | 2017-06-13 | 蒋世芬 | 血栓性静脉炎的治疗药物 |
CN109260397A (zh) * | 2017-07-18 | 2019-01-25 | 鲁南制药集团股份有限公司 | 一种治疗眼底血管性疾病的中药组合物 |
CN109718341A (zh) * | 2017-10-31 | 2019-05-07 | 鲁南制药集团股份有限公司 | 一种治疗无菌性股骨头坏死的中药组合物 |
CN110732003A (zh) * | 2018-07-18 | 2020-01-31 | 鲁南制药集团股份有限公司 | 一种治疗脑卒中后遗症的中药组合物 |
CN110732004A (zh) * | 2018-07-18 | 2020-01-31 | 鲁南制药集团股份有限公司 | 一种治疗脑供血不足的中药组合物 |
CN111228419A (zh) * | 2018-11-28 | 2020-06-05 | 鲁南制药集团股份有限公司 | 一种脉络舒通微丸制剂及其制备方法 |
CN110123968A (zh) * | 2019-06-20 | 2019-08-16 | 鲁南制药集团股份有限公司 | 一种脉络舒通制剂的制备方法 |
WO2021042276A1 (zh) * | 2019-09-03 | 2021-03-11 | 鲁南制药集团股份有限公司 | 一种治疗骨性关节炎的联合用药物 |
WO2021042274A1 (zh) * | 2019-09-03 | 2021-03-11 | 鲁南制药集团股份有限公司 | 一种治疗骨性关节炎的中西药组合物 |
WO2021042275A1 (zh) * | 2019-09-03 | 2021-03-11 | 鲁南制药集团股份有限公司 | 一种治疗骨性关节炎的的中药组合物 |
CN114340650A (zh) * | 2019-09-03 | 2022-04-12 | 鲁南制药集团股份有限公司 | 一种治疗骨性关节炎的联合用药物 |
CN114667156A (zh) * | 2019-09-03 | 2022-06-24 | 鲁南制药集团股份有限公司 | 一种治疗骨性关节炎的中西药组合物 |
CN114470114A (zh) * | 2022-01-27 | 2022-05-13 | 山东新时代药业有限公司 | 脉络舒通制剂在制备治疗便秘药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1201787C (zh) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1425448A (zh) | 一种治疗血栓性静脉炎的药物 | |
CN1600319A (zh) | 治疗心脑血管疾病的中药组合物 | |
CN1319575C (zh) | 一种治疗跌打损伤的中药组合物及其制备方法和用途 | |
CN1600318A (zh) | 一种治疗心脑血管疾病的中药组合物 | |
CN1762967A (zh) | 甘草次酸衍生物、制备方法及其用途 | |
CN1283291C (zh) | 治疗骨折的复方制剂及其制备方法 | |
CN1166382C (zh) | 治疗糖尿病肾病的中药组合物及其制备方法 | |
CN1827130A (zh) | 丹参、丹皮有效部位制备物及复方制备方法和医疗用途 | |
CN1872199A (zh) | 一种中药组合物及其制备方法 | |
CN1559495A (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN100344315C (zh) | 一种促进骨折愈合的药物组合物及其制备方法 | |
CN1911380A (zh) | 一种中药注射制剂及其制备方法 | |
CN1903238A (zh) | 一种中药提取物、制剂及其制备方法与用途 | |
CN1923270A (zh) | 治疗良性前列腺增生症的药物及其制备方法 | |
CN1602939A (zh) | 一种用于治疗心脑血管疾病的药物组合物及其制备方法 | |
CN1820770A (zh) | 一种治疗中风的中药组合物及其制备方法 | |
CN1507352A (zh) | 植物药复方及其应用 | |
CN1319557C (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN1210048C (zh) | 一种银杏叶滴丸 | |
CN1336233A (zh) | 一种治疗乙肝的药物 | |
CN1911382A (zh) | 一种中药注射制剂及其制备方法 | |
CN1616018A (zh) | 一种提高生物利用度及药效治疗妇科疾病的制剂和制备方法 | |
CN1602883A (zh) | 一种含人参总皂苷、红花黄色素的药物组合物及其制备和应用 | |
CN1911383A (zh) | 一种中药注射制剂及其制备方法 | |
CN1569160A (zh) | 治疗心脑血管疾病的中药药物制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: LUNAN PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME OR ADDRESS: LUNAN PHARMACY CO. LTD. |
|
CP03 | Change of name, title or address |
Address after: 276005 No. 209 Hongqi Road, Shandong, Linyi Patentee after: LUNAN PHARMACEUTICAL Group Corp. Address before: 276003 No. 107, No. 1, Linxi, Shandong, Linyi Patentee before: Lunan Pharmaceutical Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000515 Denomination of invention: Medicine for curing thrombotic phlebitis Granted publication date: 20050518 License type: Exclusive License Open date: 20030625 Record date: 20100909 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000515 Date of cancellation: 20131016 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20030625 Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2019370000022 Denomination of invention: Medicine for curing thrombotic phlebitis Granted publication date: 20050518 License type: Exclusive License Record date: 20190321 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CX01 | Expiry of patent term |
Granted publication date: 20050518 |
|
CX01 | Expiry of patent term |